Moderna tries its hand at CRISPR through a new development pact with Metagenomi
Moderna has always been thinking about how mRNA could transform the gene editing space, according to Eric Huang. In fact, they looked at it about a decade ago — but at the time, they were still a small, preclinical biotech, and technology like that would take some time to mature.
Then the pandemic hit, and the rest is history.
“Now, I think it’s the right time,” said Huang, CSO of Moderna’s genomics business.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.